Navigation Links
/C O R R E C T I O N -- Mobidiag Ltd/
Date:4/21/2008

Mobidiag Releases First Microarray Based Rapid Test for Bacterial Detection

The Finnish biotechnology company Mobidiag announced today the Prove-it(TM) Bacteria test that sets a world record by being able to detect 50 dangerous bacteria simultaneously - including the widespread "superbug" MRSA. This is an important milestone in the battle against infectious diseases, most importantly life-threatening sepsis.

HELSINKI, April 21 /PRNewswire/ -- Sepsis is a growing cause of death worldwide - there are around 3 million sepsis cases annually, over 500,000 of them resulting in death. Sepsis is an infection caused by a number of micro-organisms spreading in the bloodstream. The challenge in sepsis treatment is starting adequate treatment with the appropriate antibiotics on time.

Currently, the diagnostics of causative pathogen(s) needed for the antibiotic treatment decision takes 2-5 days based on blood culturing and subsequent pathogen identification. Using Mobidiag's Prove-it(TM) Bacteria, the pathogen detection is available 1-3 days earlier compared to current diagnostics. The PCR and microarray-based test takes less than three hours to complete. Achieved time saving rationalizes antibiotic treatment and improves patient outcomes and decreases mortality considerably.

"Our Prove-it(TM) Bacteria test has all the potential to revolutionize microbial sepsis diagnostics. The test helps clinicians make better and faster decisions and provide sufficient treatment for seriously ill patients. This offers huge savings, as sepsis treatment currently consumes billions of euros annually. Our target is to have a single test that reliably detects the majority of dangerous human disease causing bacteria and Prove-it(TM) Bacteria test is an important milestone on that road," says Jaakko Pellosniemi, CEO of Mobidiag. "I strongly believe that Prove-it(TM) products will rapidly gain foothold on the multibillion microbial diagnostic markets."

Prove-it(TM) Bacteria test is initially intended for research purposes. The evaluation aiming for the European CE-IVD status enabling its use in clinical sepsis diagnostics is currently ongoing and will be completed later this year. The test will cover more than 90 % of all sepsis cases.

Founded in 2001, Mobidiag develops rapid diagnostic tests for hospital laboratories. The Prove-it(TM) Bacteria test is developed in co-operation with HUSLAB and Hospital Districts of Helsinki and Uusimaa, Finland.

Mobidiag Ltd is a Finnish biotechnology company developing, producing and marketing rapid diagnostic tests to hospital laboratories. The company focuses on clinical microbial diagnostics. More information on http://www.mobidiag.com
Press photos from here http://www.mobidiag.com/media/images

Additional information:

CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. +358-40-501-1004

Press contact:

Ville Lehtovirta, Text 100 Conexio, tel. +358-50-346-6946

ville.lehtovirta@conexio.fi


'/>"/>
SOURCE Mobidiag Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci ... used in leading laboratories all over the globe. Their cute firefly logo has ... manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle Plating System 3 ... to address fractures of the distal tibia and fibula. This system marks Acumed's ... System 3 is composed of seven plate families that span the lateral, medial, ...
(Date:5/25/2016)... ... 2016 , ... Scientists at the University of Athens say they have evidence ... hampering the research that could lead to one good one. Surviving Mesothelioma has just ... , The team evaluated 98 mesothelioma patients who got a second ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical ... (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for the ... granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):